Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) filled more than 77000 prescriptions for BELVIQ in the first quarter. The quantity filled in this quarter was way more than what the company did in the last quarter. If the information provided by IMS Health is taken into consideration, then one can see that ARNA has grown by 31% on YOY basis in filling up the prescriptions. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) net profit margin is -30.20% and weekly performance is -1.60%. On last trading day company shares ended up $6.15. Analysts mean target price for the company is $8.25. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) distance from 50-day simple moving average (SMA50) is -3.57%.
RetailMeNot Inc (NASDAQ:SALE) CEO G Cotter Cunningham sold 21,000 shares of the company’s stock in a transaction that occurred on Friday, May 30th. The stock was sold at an average price of $25.68, for a total transaction of $539,280.00. Following the completion of the sale, the chief executive officer now directly owns 385,341 shares in the company, valued at approximately $9,895,557. RetailMeNot Inc (NASDAQ:SALE) shares fell -1.54% in last trading session and ended the day on $25.50. SALE Gross Margin is 93.50% and its return on assets is 2.30%. RetailMeNot Inc (NASDAQ:SALE) quarterly performance is -38.95%.
On May 21, 2014, United Online, Inc. (NASDAQ:UNTD) entered into an Office Lease with LNR Warner Center IV, LLC (the “Landlord”), for 29,576 rentable square feet located at 21255 Burbank Boulevard, Woodland Hills, California (the “Lease”), which the Company intends to occupy as its new headquarters office. The Lease commencement date is expected to be October 1, 2014. The term of the Lease is six years, with a right to extend the term for an additional five years. United Online, Inc. (NASDAQ:UNTD) ended the last trading day at $10.92. Company weekly volatility is calculated as 3.39% and price to cash ratio as 2.30. United Online, Inc. (NASDAQ:UNTD) showed a positive weekly performance of 2.82%.
Biogen Idec Inc (NASDAQ:BIIB), ranked No. 48, was upgraded to overweight from neutral by JPMorgan on Thursday. The bank cited positive opinions of oral multiple-sclerosis drug Tecfidera and raised the biotech’s price target to 375 from 300. Last month, Biogen guided 2014 earnings above Wall Street’s expectations despite Q1 earnings missing views. Biogen Idec Inc (NASDAQ:BIIB) shares moved down -0.15% in last trading session and was closed at $319.37, while trading in range of $317.93 – $322.25. Biogen Idec Inc (NASDAQ:BIIB) year to date (YTD) performance is 14.24%.
Japanese drug manufacturer, Eisai Co., Ltd (ADR) (OTCMKTS:ESALY) and its research and development subsidiary KAN Research Institute, Inc. (KRI) have officially commenced full-scale operation of their new research facility in Kobe, Hyogo prefecture. Eisai Co., Ltd (ADR) (OTCMKTS:ESALY) on last trading day company shares ended up $40.91.